Xiaojia Wang, PhD

Education

• 09/1999-12/2004, PhD in Animal Virology, China Agricultural University, Beijing, China

• 09/1995-07/1999, BS in Veterinary Microbiology, China Agricultural University, Beijing, China

Training and Professional Experience

• 2013-present, PhD supervisor, China Agricultural University College of Veterinary Medicine, Beijing, China,

• 2007-present, Associate Professor of China Agricultural University, Beijing, China

• 2010-2011, Assistant Professor of Microbiology, The University of Chicago, IL, USA

Research Interests

Dr. Wang has directed independent research projects on molecular mechanisms of viral pathogenesis and development of novel antiviral agents. She has published, as first or corresponding author, 50 refereed papers.

Awards and Honors

• 2020, Teacher student co creation team, Second Prize of Beijing, Sixth China Internet plus student innovation and entrepreneurship competition, China

• 2020, National Popular Science Explanation Competition, Excellence Award, selection and promotion by Ministry of Education, sponsored by the Ministry of Science and Technology and Ministry of Education, China

• 2017-2019, The outstanding teacher's ethics award of China Agricultural University, Beijing, China

• 2011, In recognition of service as scientist and scholar, The University of Chicago, IL, USA

• 2011, Program for New Century Excellent Talents in University, Ministry of Education Department of Higher Education of China

• 2006, Distinguished Ph.D. Dissertation Award, Ministry of Education of China

Teaching

Graduate Students

• 2006-present, Protein and Protein Technology

• 2016-present, Seminar for Ph.D Candidates

Undergraduate Students

• 2020-present, Introduction to human and animal coronavirus

• 2018-present, Basis of animal cell biology

• 2007-2015, Veterinary Parasitology

• 2018-present, Veterinary Biotechnology

Service

• 2010-present, Long term reviewer for journal of Progress in Biochemistry and Biophysics

• 2016-present, Editorial Board Member of Journal of Veterinary Science

Selected Publications

Refereed Journal Papers（* Corresponding author）

• Kong, Z.M., Sandhu, H.S., Qiu, L., Wu, J., Tian, W.J., Chi, X.J., Tao, Z., * Yang, C.J., * Wang, X.J.* Virus Dynamics and Decay in Evaporating Human Saliva Droplets on Fomites. Environmental Science Technology. 2022, 29. doi: 10.1021/acs.est.2c02311.   IF= 11.375

• Li CC, Chi XJ, Wang J, Potter A, Wang XJ,* Yang CJ.* Small Molecule RAF265 as an Antiviral Therapy Acts Against HSV-1 by Regulating Cytoskeleton Rearrangement and Cellular Translation Machinery. Journal of Medical Virology. 2022, doi:10.1002/jmv.28226. IF= 20.693

• Han, S.C., Sun, S.Q., Li,  Q., Zhang, Z.H., Dong, H., Sun, M.M., Wu, W.X., Wang, X.J.,* Guo, H.C., * Ribosomal protein L13 promotes IRES-driven translation of FMDV in helicase DDX3-dependent manner. Journal of Virology, 2020, 16, doi:10.1128/JVI.01679-19.  IF= 6.549

• Lu, J.J., Yuan, W.Z., Zhu, Y.P., * Hou, S.H., * Wang, X.J.,* Latent pseudorabies virus infection in medulla oblongata from quarantined pigs. Transboundary Emerging Diseases, 2021, 00:1–9.  IF= 4.521

• Li, C.C., Wang, X.J.,* Wang, H.C.R.,* Repurposing of host-based therapeutics to control coronavirus and influenza virus. Drug Discovery Today, 2019. pii: S1359-6446(18)30380-5.  IF= 8.369

• Meng, W., Wang, X.J.,* Wang, H.C.R., * Targeting nuclear proteins for control of viral replication. Critical Reviews in Microbiology, 2019, 21:1-19.  IF= 7.391

• Meng, W., Han, S.C., Li, C.C., Dong, H.J., Wang, X.J.,* Multifunctional viral protein 34.5 manipulates nucleolar protein NOP53 for optimal viral replication of HSV1. Cell Death Disease, 2018, 9:103.  IF= 9.685

• Li, C.C., Dong, H.J., Wang, P., Meng, W., Chi, X.J., Han, S.C., Ning, S., Wang, X.J.,* Cellular protein GLTSCR2: a valuable target for the development of broad-spectrum antivirals. Antiviral Research, 2017, 142:1-11.  IF= 10.103

• Li, C.G., Tang, W., Chi, X.J., Dong, Z.M., Wang, X.X., Wang, X.J. * Cholesterol tag at N-terminal of the relatively broad spectrum of fusion inhibitory-peptide targets earlier stage of fusion glycoprotein activation and increases peptide’s antiviral potency in vivo. Journal of Virology, 2013, 87, 9223-9232.  IF= 6.549

• Wang, X.J., Patenode, C., Roizman, B. The US3 protein kinase of HSV-1 cycles between the cytoplasm and nucleus and interacts with PDCD4 to block apoptosis. PNAS, 2011, 108 (35), 14632-6. IF= 12.779

Book (Unique author)

• Xiao-Jia Wang. Application of Protein Technology in Virology, China Science and Technology Press, 2015, 270000 words, under the sponsorship of China Association for Science and Technology.

 Patents (First author)

• HR2-mimical codes and proteins and their applications. Zl 200610144153.9

• Novel peptides against virus mix-infections. Zl 201010121830.1

• Design and modification of the efficient and long-acting peptide against Newcastle disease virus infection. Zl 201210170743.

• A virus culture medium that can optimize the replication of various viruses. Zl 201510080767.4

• Application of synthetic protein 210 in optimal viral replications. Zl 201610081938.X

• A natural compound presents broad antiviral. Zl 201710719849.8

• A broad-spectrum antiviral drug or composition. Zl 201910664898.5

• Virus enrichment and preservation methods. Zl 202210260475.9